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We have previously shown that a dengue virus type 1 DNA vaccine expressing premembrane (prM) and envelope (E) genes
was immunogenic in mice and monkeys and that rhesus monkeys vaccinated with this construct were completely to partially
protected from virus challenge. In order to improve the immunogenicity of dengue DNA vaccines, we have evaluated the
effect of lysosome targeting of antigens and coimmunization with a plasmid expressing GM-CSF on antibody responses. A
dengue virus type 2 candidate vaccine containing prM and E genes was constructed in which the transmembrane and
cytoplasmic regions of E were replaced by those of the lysosome-associated membrane protein (LAMP). The modified
vaccine construct expressed antigen that was colocalized with endogenous LAMP in lysosomal vesicles of transfected cells,
whereas the antigen expressed from the unmodified construct was not. It was hypothesized that targeting of antigen to the
lysosomal compartment will increase antigen presentation by MHC class II, leading to stronger CD4-mediated immune
responses. Mice immunized with the modified construct responded with significantly higher levels of virus neutralizing
antibodies compared to those immunized with the unmodified construct. Coimmunization of mice with a plasmid expressing
murine GM-CSF enhanced the antibody response obtained with either the unmodified or the modified construct alone. The
highest antibody responses were noted when the modified construct was coinjected with plasmid expressing the GM-CSF
gene. These results could form the basis for an effective tetravalent dengue virus DNA vaccine. © 2001 Academic Press
Key Words: dengue; DNA vaccine; LAMP; GM-CSF; neutralizing antibody; lysosome targeting.
MINTRODUCTION
Dengue is one of the most important arboviral dis-
eases of humans. The four antigenically distinct sero-
types of dengue virus (Genus Flavivirus, Family Flaviviri-
dae) cause an estimated 100 million infections resulting
in widespread dengue fever (DF) and at least 250,000
cases of dengue hemorrhagic fever (DHF) each year
(Halstead, 1988). These viruses are transmitted primarily
by the mosquito Aedes aegypti and are endemic
throughout the tropical and subtropical regions of the
world. A major expansion of dengue transmission has
occurred throughout the tropical Americas accompanied
by a large increase in the number of DHF cases. Despite
the public health importance of DF and DHF, no effective
control measure is available other than vector reduction,
which has proven difficult and costly to sustain over time
(Gubler and Trent, 1994). Although vaccines are available
for two related flaviviruses, yellow fever (YF) virus and
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74Japanese encephalitis (JE) virus (Barrett, 1997a,b), de-
cades of effort have not produced a successful dengue
virus vaccine. Live attenuated dengue viruses, while im-
munogenic, have been associated with high reactoge-
nicity and clinical complications (Edelman et al., 1994;
cKee et al., 1987). Inactivated dengue viruses have
been reported to be less immunogenic (Schlesinger,
1977), and recombinant dengue proteins have failed to
protect nonhuman primates from homologous dengue
virus challenge (Deubel et al., 1988; Eckels et al., 1994).
We have been exploring DNA vaccine technology in
which plasmids expressing appropriate viral antigens
are used for immunization. This approach has been
shown to induce an immune response in animal models
against a number of different viruses, including several
flaviviruses (Colombage et al., 1998; Konishi et al., 1998;
Phillpotts et al., 1996; Schmaljohn et al., 1997). We have
previously shown that a dengue-2 DNA vaccine contain-
ing the genes for premembrane (prM) and 92% of enve-
lope (E) protein induced neutralizing antibody response
in mice (Kochel et al., 1997) and the vaccinated mice had
a higher survival rate following dengue-2 virus challenge
(Porter et al., 1998). When four different dengue-1 DNA
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75DENGUE-LAMP CHIMERIC DNA VACCINEvaccine candidates expressing truncated or full-length E
with or without prM were compared, we observed that
the candidate expressing prM and full-length E produced
virus-like particles and elicited long-lasting neutralizing
antibodies in mice (Raviprakash et al., 2000a). This den-
gue-1 vaccine was further shown to be immunogenic in
nonhuman primates and afforded complete to partial
protection from challenge (Kochel et al., 2000; Ravi-
rakash et al., 2000b). In all these studies, the virus
eutralizing antibody levels were low. We are now at-
empting to modify the dengue DNA vaccine to achieve
nhanced antibody response.
Although DNA vaccines give rise to antigen-specific
TL responses in vaccinated animals, they have per-
ormed poorly with regard to stimulation of antibody
roduction. This is probably because the majority of the
ndogenously produced antigen is sequestered into the
ajor histocompatibility complex (MHC) class I pathway
f antigen presentation. For dengue viruses, it is believed
hat antibody can afford protection against infection and
hat neutralizing antibody is an important component of
his protection. It is therefore desirable that a dengue
accine produce high titers of neutralizing antibody. For
uccessful immune response and antibody production, it
s critical that the antigen be presented to CD41 T helper
cells by the class II MHC molecules. The MHC class II
antigen processing and presentation pathway that con-
ventionally operates in professional antigen-presenting
cells (APC) is accessed by endocytosis or phagocytosis
of extracellular antigen. This pathway, therefore, may not
operate efficiently in cells that take up the vaccine DNA
and synthesize the antigen intracellularly. It may thus be
beneficial to target the antigen expressed by DNA vac-
cines to the lysosomal compartment for degradation and
successful loading onto MHC class II molecules, conse-
quently leading to enhanced CD41 helper T cell re-
ponse.
The lysosome-associated membrane protein (LAMP)
s a major protein of mouse embryo 3T3 cells and is
pecifically associated with the lysosomal membrane. A
etrapeptide Tyr-X-X-hydrophobic residue sequence in
he carboxyl-terminal sequence of LAMP has been iden-
ified as the sequence responsible for its targeting to the
ysosomal membrane (Guarnieri et al., 1993). Viral pro-
teins to which the carboxy-terminal sequence of LAMP
has been fused have been shown to accumulate in the
lysosomes of transfected cells (Rowell et al., 1995). We
have constructed dengue-2 DNA vaccine candidates that
express prM and E (D2ME) or prM and E-LAMP (D2MEL)
chimeric protein. Here we report that the protein ex-
pressed by D2MEL and not D2ME is colocalized with
endogenous LAMP. When injected into mice, D2MEL
elicited an enhanced antibody response, which was fur-
ther augmented by coimmunization with a plasmid ex-
pressing mouse granulocyte-monocyte colony stimulat-
ing factor (GM-CSF).RESULTS
Results discussed in this section are representative of
three independent experiments utilizing separate
batches of purified DNA. The mice were vaccinated with
three doses of DNA in quick succession on days 1, 11,
and 21. This immunization schedule was borrowed from
our earlier studies (Porter et al., 1998) where the intent
was to challenge mice when they are still young. How-
ever, similar antibody responses were observed when
mice were given two doses on days 1 and 28.
D2MEL vaccine is more immunogenic than D2ME
The results of an experiment in which 1040D2ME (den-
gue-2 prM and E genes cloned into vector pVR1040) was
compared with 1040D2MEL (1040D2ME–LAMP chimera)
for immunogenicity in mice are summarized in Fig. 1.
Groups of mice (n 5 5) were immunized on days 1, 11,
nd 21 with 50 mg of VR1040, 1040D2ME, or 1040D2MEL
DNA with or without VR1701 (plasmid expressing murine
GM-CSF). No anti-dengue antibody was detected in mice
vaccinated with control DNAs VR1040 and VR1701 (not
shown). None of the 5 mice immunized with 1040D2ME
seroconverted on day 30, and only 2 had seroconverted
on day 120 (Fig. 1A). In contrast, all the 5 mice immunized
with 1040D2MEL had seroconverted on day 30 and their
antibody levels remained stable through day 120 (Fig. 1B).
Codelivery of a plasmid expressing murine GM-CSF
augments antibody response
We evaluated the effect of coadministration of DNA
expressing the murine GM-CSF gene by vaccinating
groups of mice (n 5 5) with 50 mg 1040D2ME or
1040D2MEL, plus 10 mg VR1701 plasmid. It was clear
that the addition of VR1701 had a marked effect on the
antibody response. All 5 mice seroconverted on day 30
after immunizing with D2ME 1 VR1701 compared to no
seroconversion when injected with D2ME alone (Figs. 1A
and 1C). Further, the antibody levels increased dramati-
cally by day 120. In mice that were vaccinated with
D2MEL 1 VR1701, the highest antibody levels were seen
on day 30 and were sustained through day 120 (Fig. 1D).
Virus neutralization
The ability of antibody produced in response to vac-
cines to neutralize dengue virus in vitro was measured
by the plaque reduction neutralization test (PRNT). The
neutralization of virus at each dilution of the serum is
shown in Fig. 2. Some virus neutralizing activity (,50%)
was present in the pooled sera from the group vacci-
nated with the control plasmids VR1040 and VR1701. This
activity, which was observed only on day 30, disap-
peared in later bleeds. Sera from the group vaccinated
with 1040D2ME also showed low neutralizing activity
that persisted through day 60. In contrast, sera from mice
1
1
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76 RAVIPRAKASH ET AL.immunized with 1040D2MEL had 50% neutralization ti-
ters (PRNT50) of 48–270 from day 30 to 120 (Fig. 2 and
Table 1). Coimmunization with pVR1701 markedly in-
creased the PRNT50 titers for both 1040D2ME and
040D2MEL immunized mice. Mice vaccinated with
040D2ME 1 VR1701 had PRNT50 titers of 40–120 from
day 60 to 120. The highest titers of 340–1250 from day 30
to 120 were seen in mice vaccinated with 1040D2MEL 1
VR1701. These titers persisted for more than a year (not
shown).
Antibody avidity
In order to determine whether there was a qualitative
difference in the antibody produced by different immuni-
zations, we evaluated the avidity of antibody to bind
antigen. Each serum sample was diluted so as to obtain
an absorbance of 0.8–1.5 by ELISA. The ability of anti-
body to bind antigen in the presence or absence of 6 M
urea was measured as described under Materials and
Methods, and an avidity index (AI) for each serum sam-
ple was calculated. There was no significant difference
in the avidity of antibody from mice vaccinated with
D2ME 1 VR1021, D2MEL, or D2MEL 1 VR1021 (Fig. 3).
The mean AI for these groups was 44.4, 51.7, and 45,
respectively.
Antigen expressed from D2MEL chimeric vaccine
construct is colocalized with endogenous LAMP
NIH3T3 cells were transfected with 1040D2ME or
FIG. 1. Antibody response in mice vaccinated with 1040D2ME or
(VR1701). Mice (n 5 5) were vaccinated on days 1, 11, and 21 with 1040D
(D). Anti-dengue antibody titer in sera of days 30 and 120 from individu
of the samples.1040D2MEL and the expression and cellular steady-
state localization of the dengue virus antigen were com-pared to those of the endogenous LAMP proteins of the
cell by dual fluorescence staining and confocal micros-
copy. Endogenous LAMP showed the typical localization
in lysosomal bodies in the cells transfected with either
the wild type (1040D2ME) or the modified (1040D2MEL)
construct (Figs. 4A and 4E). When cells were stained
using the dengue-2 E-specific monoclonal antibody 3H5,
those transfected with the wild-type 1040D2ME showed
the expected membrane reticular distribution associated
with viral envelope protein (Fig. 4B). In contrast, the
chimeric protein in 1040D2MEL transfected cells was
distributed in a pattern similar to that of the endogenous
LAMP (Fig. 4F). When Figs. 4E and 4F are superimposed,
extensive colocalization of the chimeric D2MEL protein
with endogenous LAMP protein was observed (Figs. 4G
and 4H). No such colocalization of the unmodified D2ME
was evident when Figs. 4A and 4B were superimposed
(Figs. 4C and 4D).
DISCUSSION
We have shown that a modified dengue virus E protein
in which the ectodomain of E is fused with the trans-
membrane and cytoplasmic domains of LAMP-1 is effec-
tively targeted to the lysosomes of NIH3T3 cells where it
is colocalized with endogenous LAMP. Further, we have
shown that the vaccine construct expressing this chi-
meric antigen elicited markedly better neutralizing anti-
body responses than its wild-type counterpart and that
the antibody responses could be further augmented by
MEL with or without plasmid expressing the murine GM-CSF gene
A), 1040D2MEL (B), 1040D2ME 1 VR1701 (C), or 1040D2MEL 1 VR1701
for each group was detected by ELISA using twofold serial dilutions1040D2
2ME (coimmunization with a plasmid expressing the mouse
GM-CSF gene.
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77DENGUE-LAMP CHIMERIC DNA VACCINEPreviously, we have shown that a dengue virus type 1
DNA vaccine expressing prM and E genes was immu-
nogenic in mice (Raviprakash et al., 2000a). In rhesus
acaques, as well as in the New World Aotus monkeys,
his dengue-1 vaccine elicited immune responses that
fforded complete to partial protection from viremia upon
irus challenge (Kochel et al., 2000; Raviprakash et al.,
000b). Neutralizing antibodies are thought to be of par-
FIG. 2. Plaque reduction neutralization test. Sera from antibody-po
1040D2ME 1 VR1701, 1040D2MEL, and 1040D2MEL 1 VR1701 were p
0, 90, and 120 were used, and the percentage virus neutralization for
long with the standard error.mount importance for protection against dengue dis-
ase (Kliks et al., 1988). Because DNA vaccines cause
c
antracellular synthesis of foreign antigens, the antigens
ore efficiently enter the MHC class I pathway of anti-
en presentation, leading to better cellular immune re-
ponses than humoral immune responses. To increase
he antibody responses, it is important that the antigen
e efficiently presented by class II MHC to CD41 helper
cells. Therefore, it may be beneficial to target the
ntigen to intracellular compartments that are rich in
ice for groups injected with VR1040, VR1040 1 VR1701, 1040D2ME,
nd used in PRNT starting at 1:20 dilution. Sera collected on days 30,
roup (mean of duplicate assay) is shown for various serum dilutions,sitive m
ooled alass II MHC. Several reports have shown that LAMP
nd MHC II are colocalized in specialized cellular vesi-
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78 RAVIPRAKASH ET AL.cles, called MIIC of the endosomal/lysosomal vesicular
pathway of APC such as dendritic cells and macro-
phages (Harding and Geuze, 1993; Kleijmeer et al., 1995;
eters et al., 1995; Turley et al., 2000). It has been shown
hat proteins, when encoded by plasmids engineered to
ontain a ER translocation signal sequence and the
AMP transmembrane and cytoplasmic domains, are
irected to the MHC II compartment (Guarnieri et al.,
1993). This LAMP trafficking of DNA vaccine encoded
antigens, including human papilloma virus E7, HIV gp160,
and carcino-embryonic antigen, has been shown to re-
sult in a marked increase in both the cellular and the
humoral immune responses in vaccinated mice (Lin et
l., 1996; Nair et al., 1998; Rowell et al., 1995; Ruff et al.,
997; Wu et al., 1995). By applying this LAMP trafficking
echnology, we have shown here that the dengue-2/
AMP chimeric vaccine construct elicited significantly
mproved antibody response compared to the unmodi-
ied dengue-2 vaccine construct.
Low virus neutralizing activity was also observed on
ay 30, in the sera of control mice injected with empty
ector DNA and VR1701. This activity disappeared from
ater bleeds. It is possible that one or more serum factors
esulting from the injection of GM-CSF plasmid on day 21
ould have resulted in nonspecific virus neutralization in
he day 30 sample. Modulation of dengue virus infection
y cytokines has been reported (Diamond et al., 2000).
era from mice immunized with unmodified 1040D2ME
lso contained low neutralizing activity up to day 60.
imilar low levels of neutralizing antibody with a similar
engue-2 DNA vaccine construct were recently reported
Konishi et al., 2000). Our interpretation of these data is
hat this vaccine encoding wild-type antigen possibly
licited some degree of neutralizing antibody, but in the
bsence of CD41 T-helper cell activation, the response
was slight and transient.
Immune responses to foreign antigens have also been
modulated by codelivery of plasmids expressing various
cytokine genes. These have been termed genetic adju-
vants. Different cytokine genes have been reported to
TABLE 1
50% Virus Neutralization Titers (PRNT50)
Vaccine Day 30 Day 60 Day 90 Day 120
R1040 1 VR1701 0 0 0 0
1040D2ME 0 0 0 0
1040D2MEL 48 115 94 270
1040D2ME 1 VR1701 0 120 40 120
1040D2MEL 1 VR1701 340 510 1250 1000
Note. For each group, sera from mice that seroconverted were
pooled. The pooled sera were used in a plaque reduction neutralization
test and PRNT50 titers were determined by probit analysis.modulate different aspects of immune response. Using
HIV DNA immunogens, Kim et al. (1998) have shown that Moinjection with Th-2-type cytokine genes (IL-4, IL-5, IL-
0) resulted in increased humoral immune response,
h-1-type cytokine genes enhanced humoral (IL-2, IL-18)
nd CTL (IL-15) responses. Xiang et al. (1997) have re-
orted that among nine different cytokine genes tested
s genetic adjuvants, GM-CSF consistently enhanced
he immune responses. Intramuscular injection of rabies
irus DNA vaccine expressing the glycoprotein along
ith GM-CSF plasmid led to increased B and T-helper
ell activity to rabies virus (Xiang and Ertl, 1995). It has
een recently shown that intramuscular injection of plas-
id expressing GM-CSF attracts infiltrates including
D11c1 immature dendritic cells and that immune en-
ancement is associated with the presence of CD11c1
cells in the infiltrates (Haddad et al., 2000). We have
shown here that when the unmodified dengue-2 DNA
vaccine was coinjected with GM-CSF plasmid, signifi-
cantly higher levels of neutralizing antibody were ob-
tained. This effect was similar to that obtained by den-
gue-2/LAMP chimeric DNA vaccine in the absence of the
adjuvant. Evidently, LAMP targeting and the use of GM-
CSF as genetic adjuvant had similar immune enhance-
ments, albeit by different mechanisms. When these two
techniques were used together, as in coinjection of
D2MEL and GM-CSF plasmid, remarkably high neutral-
izing antibodies were obtained.
Day 120 antibody titers (ELISA) for mice injected with
1040D2ME 1 VR1701 were higher than those for mice
injected with 1040D2MEL. Yet the sera of 1040D2MEL
injected mice had higher virus neutralizing activity (com-
pare Fig. 1 and Table 1). To see whether there was a
qualitative difference in the antibodies of these two
groups of mice, we measured antibody avidity. There
FIG. 3. Antibody avidity. Antibody avidity for sera from individual mice
vaccinated with 1040D2ME 1 VR1701, 1040D2MEL, or 1040D2MEL 1
VR1701 was measured by ELISA in the presence and absence of 6 M
urea. Avidity index (AI) was calculated as 100 3 (OD[1urea]/OD[2urea]).
ean AI for each group is shown with standard error.
superim
79DENGUE-LAMP CHIMERIC DNA VACCINEwas no significant difference in antibody avidity for the
various groups of mice.
It is clear from the results that a significant improve-
ment in the virus neutralizing antibody response against
dengue virus type 2 could be obtained by a combination
of LAMP-targeting and coimmunization with GM-CSF
plasmid. Since tetravalent immunity is key to a success-
ful dengue vaccine, further studies with other dengue
serotypes are currently under way. In addition, testing
these concepts in nonhuman primates, and possibly in
humans, is warranted.
MATERIALS AND METHODS
Cells, virus, and antibodies
Vero cells and NIH3T3 cells were obtained from ATCC
(Rockville, MD) and were grown according to the sup-
plier’s specifications in MEM (Earl’s salts) containing 10%
fetal bovine serum (FBS). Dengue virus type 2 New
Guinea C strain (ATCC) was propagated in Vero cells to
an average titer of 106 plaque-forming units (PFU) per
milliliter. The virus was concentrated by precipitation
with polyethylene glycol (7%) in the presence of 2.5%
FIG. 4. Colocalization of chimeric D2MEL protein with endogenous L
or 1040D2MEL (E–H) were double stained with anti-LAMP antibody (A
examined by confocal microscopy. Colocalization was visualized by
enlargements of images C and G, respectively.NaCl. The virus pellet was washed and the concentrated
virions were used to coat ELISA plates for antibodydetection. Dengue-2 polyclonal hyperimmune ascitic
fluid was obtained from ATCC. Monoclonal antibodies
3H5 (specific for dengue-2 envelope protein) and 1D4B
(specific for mouse LAMP protein) were obtained from
supernatants of corresponding hybridoma cultures.
Vaccine constructs
Dengue virus type 2 (strain New Guinea C) sequence
between nucleotides 367 and 2421 (Irie et al., 1989) was
amplified by reverse transcriptase–polymerase chain re-
action (RT-PCR) of viral RNA using MMuLV reverse tran-
scriptase (Life Technologies, Inc., Gaithersburg, MD) and
Taq polymerase (Perkin—Elmer, Palo Alto, CA). These
sequences included the carboxy-terminal sequences of
the capsid serving as leader sequence, the prM, a sec-
ond hydrophobic signal sequence, and the E gene. The
forward primer contained the Kozak sequences and the
reverse primer contained a translational stop codon. The
amplified sequences were cloned into vector pVR1040
(Vical, Inc., San Diego, CA), to produce 1040D2ME. This
vector is similar to pVR1012 (Hartikka et al., 1996), but
has four copies of the mouse immunostimulatory se-
quence (ISS) containing the CpG motif. 1040D2MEL was
rotein in NIH3T3 cells. NIH3T3 cells transfected with 1040D2ME (A–D)
d 3H5 monoclonal antibody specific for dengue-2 E protein (B, F) and
position of images A and B (C) and of E and F (G). D and H areAMP p
, E) anconstructed by replacing the carboxy-terminal 129 bp of
the E gene with sequence encoding the membrane an-
t
e
w
f
n
e
a
L
T
t
u
a
m
I
i
s
a
w
A
s
o
b
i
w
t
s
E
(
80 RAVIPRAKASH ET AL.chor and cytoplasmic domains of LAMP-1 (120 bp). A
cartoon of the proteins expressed from these constructs
is shown in Fig. 5. Plasmid VR1701 expressing the mu-
rine GM-CSF gene was from Vical Inc. All vaccine DNAs
were purified by alkaline lysis (Maniatis et al., 1984)
followed by chromatography on a Sepharose S-1000
(Pharmacia) column (Horn et al., 1995).
Transfection and immunofluorescence
NIH3T3 cells were transfected with plasmids D2ME
(encoding dengue-2 prM and E), D2MEL (encoding den-
gue-2 prM-E-LAMP chimera), or empty vector plasmid
pVR1040 using FuGene 6 (Boehringer Mannheim). Cells
were grown on coverslips in 6-well tissue culture plates,
and 2 mg plasmid with 6 mg FuGene 6 was used per
ransfection. Forty-eight hours after transfection, the cov-
rslips were transferred to a 24-well plate and washed
ith PBS (phosphate-buffered saline). The cells were
ixed with 2% paraformaldehyde and blocked with 4%
ormal goat serum and 0.1% saponin in PBS. Dengue
nvelope was detected with 3H5 monoclonal antibody
nd FITC-labeled goat anti-mouse IgG. Endogenous
AMP was detected with 1D4B monoclonal antibody and
exas red-labeled goat anti-rat IgG. The coverslips were
hen mounted onto glass slides using ProLong (Molec-
lar Probe). Fluorescence microscopy and digital image
cquisition were carried out with a Nikon TE300 confocal
icroscope.
mmunization of mice
Unless otherwise indicated, all immunizations were
ntradermal near the base of the tail with 50 mg for the
vaccine or control plasmid and 10 mg of the VR1701 (a
plasmid expressing murine GM-CSF gene) where indi-
cated. Six groups (n 5 5) of mice were inoculated with
three doses on days 1, 11, and 21 as follows: Group A:
FIG. 5. Dengue-2 prM/E (D2ME) and prM/E/LAMP (D2MEL) chimeric
vaccine constructs. A cartoon of prM and E expressed from unmodified
and chimeric dengue-2 vaccine constructs (A) and representation of
the two vaccine constructs (B).pVR1040; Group B: pVR1040 1 VR1701; Group C:
1040D2ME; Group D: 1040D2ME 1 VR1701; Group E:1040D2MEL; Group F: 1040D2MEL 1 VR1701. Blood
amples were collected on day 30 and monthly there-
fter, by the periorbital route. Sera from the samples
ere stored frozen until used.
ntibody analyses
Measurements of anti-dengue antibody titers in the
erum samples were done using twofold serial dilutions
f sera in an ELISA according to Ansari et al. (1993)
except that polyethylene glycol (PEG) precipitated den-
gue-2 virions were used as the antigen. End-point titers
were defined as the highest dilution of the serum that
produced an absorbance that was 3 standard deviations
or more higher than the controls.
Antibody avidity measurements were performed by
comparing antibody binding to antigen in the presence
and absence of 6 M urea in a standard ELISA (Narita et
al., 1998). Briefly, sera were diluted so as to obtain a
standard ELISA OD value of between 0.8 and 1.5. ELISA
was performed in duplicate microtiter plates. After anti-
body binding, both plates were washed three times with
wash buffer. To one plate, 200 ml of wash buffer was
added per well and to the other plate, 200 ml of wash
uffer containing 6 M urea was added. Both plates were
ncubated for 5 min at room temperature. The buffers
ere removed and the plates were washed three more
imes with wash buffer. Incubations with conjugate and
ubstrate were carried out according to the standard
LISA protocol. The AI was calculated as 100 3
OD[1urea]/OD[2urea]).
Virus neutralization titers were measured by a PRNT
as described (Russell et al., 1967). Serial twofold dilu-
tions of the serum samples were used and the PRNT50
titers were determined by probit analysis.
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